Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

NCT00952380

Last updated date
Study Location
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Venous Thromboembolism
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0-18
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

-

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


-

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Venous ThromboembolismDalteparin vs Unfractionated Heparin For The Prevention Of Venous Thromboembolism (VTE) In Hospitalized Acutely Ill Medical Patients NCT00445328
  1. Hyderabad, Andhra Pradesh
  2. Ahmedabad, Gujarat
  3. Trichur, Kerala
  4. Indore, Madhya Pradesh
  5. Chennai, Tamil Nadu
  6. Kolkata, West Bengal
  7. Kolkata, West Bengal
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Venous ThromboembolismAn Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin® NCT01046903
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Venous ThromboembolismFragmin for the Treatment of Acute VTE in Pediatric Cancer Patients NCT00952380
  1. Aurora, Colorado
  2. Washington, District of Columbia
  3. Jacksonville, Florida
  4. Jacksonville, Florida
  5. Tampa, Florida
  6. Tampa, Florida
  7. Tampa, Florida
  8. Tampa, Florida
  9. Tampa, Florida
  10. Detroit, Michigan
  11. Kansas City, Missouri
  12. Memphis, Tennessee
  13. El Paso, Texas
  14. El Paso, Texas
  15. Houston, Texas
  16. Houston, Texas
  17. Houston, Texas
  18. Oslo,
  19. Oslo,
  20. Kazan, Republic Tatarstan
  21. Kazan, Republic Tatarstan
  22. Moscow,
  23. Ljubljana,
  24. Ljubljana,
  25. Boadilla del Monte, Madrid
  26. Boadilla del Monte, Madrid
ALL GENDERS
0+
years
MULTIPLE SITES
Venous ThromboembolismApixaban for the Acute Treatment of Venous Thromboembolism in Children NCT02464969
  1. Ottawa, Ontario
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Phoenix, Arizona
  6. Loma Linda, California
  7. Loma Linda, California
  8. Loma Linda, California
  9. Madera, California
  10. Oakland, California
  11. Oakland, California
  12. Oakland, California
  13. Palo Alto, California
  14. Palo Alto, California
  15. Palo Alto, California
  16. Roseville, California
  17. Sacramento, California
  18. Sacramento, California
  19. San Bernardino, California
  20. San Francisco, California
  21. San Francisco, California
  22. San Francisco, California
  23. Aurora, Colorado
  24. Aurora, Colorado
  25. Hartford, Connecticut
  26. Wilmington, Delaware
  27. Washington, District of Columbia
  28. Hollywood, Florida
  29. Hollywood, Florida
  30. Orlando, Florida
  31. Orlando, Florida
  32. Orlando, Florida
  33. Orlando, Florida
  34. Tampa, Florida
  35. West Palm Beach, Florida
  36. West Palm Beach, Florida
  37. Atlanta, Georgia
  38. Atlanta, Georgia
  39. Atlanta, Georgia
  40. Peoria, Illinois
  41. Indianapolis, Indiana
  42. Indianapolis, Indiana
  43. Indianapolis, Indiana
  44. Iowa City, Iowa
  45. Lexington, Kentucky
  46. New Orleans, Louisiana
  47. Boston, Massachusetts
  48. Ann Arbor, Michigan
  49. Detroit, Michigan
  50. Detroit, Michigan
  51. Jackson, Mississippi
  52. Hackensack, New Jersey
  53. New Brunswick, New Jersey
  54. New Brunswick, New Jersey
  55. New Brunswick, New Jersey
  56. New York, New York
  57. New York, New York
  58. New York, New York
  59. New York, New York
  60. New York, New York
  61. New York, New York
  62. Syracuse, New York
  63. Durham, North Carolina
  64. Durham, North Carolina
  65. Akron, Ohio
  66. Cincinnati, Ohio
  67. Cleveland, Ohio
  68. Cleveland, Ohio
  69. Columbus, Ohio
  70. Dayton, Ohio
  71. Oklahoma City, Oklahoma
  72. Oklahoma City, Oklahoma
  73. Philadelphia, Pennsylvania
  74. Philadelphia, Pennsylvania
  75. Philadelphia, Pennsylvania
  76. Philadelphia, Pennsylvania
  77. Pittsburgh, Pennsylvania
  78. Charleston, South Carolina
  79. Charleston, South Carolina
  80. Nashville, Tennessee
  81. Nashville, Tennessee
  82. Nashville, Tennessee
  83. Houston, Texas
  84. Houston, Texas
  85. Houston, Texas
  86. San Antonio, Texas
  87. San Antonio, Texas
  88. Salt Lake City, Utah
  89. Seattle, Washington
  90. Milwaukee, Wisconsin
  91. West Allis, Wisconsin
  92. Randwick, New South Wales
  93. Sydney, New South Wales
  94. Innsbruck, Tyrol
  95. Innsbruck,
  96. Wien,
  97. Hamilton, Ontario
  98. Berlin,
  99. Duisburg,
  100. Leipzig,
  101. Munchen,
  102. Beer Sheva,
  103. Beer Sheva,
  104. Beer Sheva,
  105. Haifa,
  106. Haifa,
  107. Ramat Gan,
  108. Coimbra,
  109. Coimbra,
  110. Lisboa,
  111. Kazan, Republic Tatarstan
  112. Yekaterinburg, Sverdlovsk Region
  113. Moscow,
  114. Moscow,
  115. Boadilla del Monte, Madrid
  116. Barcelona,
  117. Barcelona,
  118. Madrid,
  119. Dnipro,
  120. Kyiv,
  121. Kyiv,
  122. Zaporizhzhia,
  123. Glasgow, Scotland
  124. Newcastle upon Tyne, Tyne & Wear
  125. Cardiff, Wales
  126. Cardiff, Wales
  127. Birmingham, WEST Midlands
  128. Birmingham,
  129. Newcastle Upon Tyne,
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Official Title  ICMJE A THREE MONTH PROSPECTIVE OPEN LABEL STUDY OF THERAPY WITH FRAGMIN(REGISTERED) (DALTEPARIN SODIUM INJECTION) IN CHILDREN WITH VENOUS THROMBOEMBOLISM WITH OR WITHOUT MALIGNANCIES
Brief Summary Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Detailed Description Primary study objectives include are to determine the pharmacodynamic (PD) profiles for treatment doses of dalteparin in pediatric subjects of different ages with cancer and venous thromboembolism (VTE), using anti-Xa (Xa) levels and a population PD analysis methodology, and to determine the median dose required to achieve therapeutic anti- Xa levels (0.5 to 1.0 International Units [IU]/mL) based on subject age and weight.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Venous Thromboembolism
Intervention  ICMJE Drug: dalteparin
dalteparin subcutaneous injection
Study Arms  ICMJE Single Arm
Single arm open-label
Intervention: Drug: dalteparin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: April 9, 2018)
38
Original Estimated Enrollment  ICMJE
 (submitted: August 4, 2009)
50
Actual Study Completion Date  ICMJE March 2018
Actual Primary Completion Date March 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

-

Exclusion Criteria:

-

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE up to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Norway,   Russian Federation,   Slovenia,   Spain,   United States
Removed Location Countries Croatia,   Germany,   Poland,   Romania
 
Administrative Information
NCT Number  ICMJE NCT00952380
Other Study ID Numbers  ICMJE FRAG-A001-201
A6301094 ( Other Identifier: Alias Study Number )
2016?000394?21 ( EudraCT Number )
2016-000394-21 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP